Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Alphamab Starts Australian Trial of PD-L1/CTLA-4 Bispecific

publication date: Oct 10, 2018

Alphamab Oncology of Suzhou has started a Phase I clinical trial of its humanized PD-L1/CTLA-4 bispecific antibody in Australia. The company has also been approved to conduct a similar China trial of the candidate, KN046. The company said KN046 is engineered to target the tumor microenvironment, reducing side effects, while its dual target mechanism increases efficacy. In preclinical studies, KN046 showed excellent anti-tumor activity, according to Alphamab, with less toxicity than the marketed CTLA-4 antibody Yervoy. Alphamab said the Australian clinical trial also demonstrated good tolerability in humans. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events


China Showcase 2020

San Francisco, USA

January 12, 2020

ChinaBio Partnering Forum 2020

Suzhou, China

May 6-7, 2020